Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the stocks that Jim Cramer shared takes on, along with navigating market shortages. Cramer highlighted the stock’s performance after the leadership change in 2023, as he remarked:

Alright, what has gotten into the stock of Teva Pharmaceutical Industries, one of the world’s largest generic drug makers? But I think it’s far more than that. After spending a few years lost in the wilderness, the company brought in a new leader, Richard Francis, at the beginning of 2023, and the stock hasn’t looked back since, nearly 400% gain from its 2022 lows. You better listen, up 54% gains over the past 12 months. This morning, Teva reported, although it had already preannounced when I was out there at the JPMorgan Healthcare conference. The quarterly results still came in higher, but… full-year forecast, some people said it was a little light. I don’t know. Initially, the stock went down 9%. That was just crazy, frankly. Then the stock stabilized after the conference call, and then it finished up more than 2%. That’s sane.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) produces medical products including generic pills, inhalers, and treatments for conditions like migraines and cancer. In addition, the company handles contract manufacturing and supplies active drug ingredients to other companies.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.